share_log

百诚医药获华安证券买入评级，收入端稳健增长，自研成果转化步入收获期

JRJ Finance ·  Aug 22 17:36  · Ratings

2024年8月22日，百诚医药获华安证券买入评级，近一个月百诚医药获得7份研报关注。

华安证券预计百诚医药2024-2026年营业收入分别为12.51亿元、15.10亿元、18.14亿元，同比增速为22.9%/20.7%/20.1%；归母净利润分别为3.09亿元、3.71亿元、4.30亿元，净利润同比增速13.6%/20.0%/16.0%。华安证券认为，随着产品管线的持续推进及成果陆续转化，有望带动百诚医药公司业绩进一步增长。

风险提示：行业竞争加剧；订单交付不及预期；自研成果转化遇阻风险等。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment